Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C

Investigative Radiology

Volumn 43, Issue 12, 2008, Pages 817-828

  Frenzel, Thomas ^a   Lengsfeld, Philipp ^a   Schirmer, Heiko ^a   Hütter, Joachim ^a   Weinmann, Hanns Joachim ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Complex stability; Contrast agent; Gd chelate; Kinetic inertia; Nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PHOSPHATE; CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; BLOOD PH; DISSOCIATION; DRUG STABILITY; FEMALE; HUMAN; INCUBATION TEMPERATURE; INCUBATION TIME; KIDNEY FAILURE; MALE; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SIMULATION; THERMOSTABILITY; BLOOD ANALYSIS; BODY TEMPERATURE; CHEMISTRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; SERUM;

BLOOD CHEMICAL ANALYSIS; BODY TEMPERATURE; CHEMISTRY; CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; SERUM;

EID: 59649103411     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181852171     Document Type: Article

References (50)

1. Knopp MV, Balzer T, Esser M, et al. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol. 2006;41:491-499.
2. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:58-62.
3. Bourrinet P, Martel E, El Amrani Al, et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:63-77.
4. Grobner T. Gadolinium - a specific trigger for the development of neph-rogenic fibrosing dermopathy and nephrogenic systemic fibrosis [erratum in Nephrol Dial Transplant. 2006;21:1745]. Nephrol Dial Transplant. 2006;21:l 104-1108.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17:2359-2362.
6. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:200-207.
7. Caravan P, Ellison JJ, McMurry T, et al. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-2352.
8. Platzek J, Blaszkiewicz P, Gries H, et al. Synthesis and structure of a new macrocyclic polyhydroxylated gadolinium chelate used as a contrast agent for magnetic resonance imaging. Inorg Chem. 1997;36:6086- 6093.
9. Kumar K, Chang CA, Francesconi LC, et al. Synthesis, stability, and structure of gadolinium (III) and yttrium (III) macrocyclic poly(amino carboxylates). Inorg Chem. 1994;33:3567-3575.
10. Lehn JM. Supramolecular chemistry-scope and perspectives: molecules, supermolecules, and molecular devices (Nobel lecture). Angew Chem bit Ed Engl. 1988;27:89-112.
11. Lauffer RB. Magnetic resonance contrast media: principles and progress. Magn Reson Q. 1990;6:65-84.
12. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents forNMR imaging: theory and design. Chem Rev. 1987;87:901- 927.
13. White DH, deLearie LA, Moore DA, et al. The thermodynamics of complexation of lanthanide (III) DTPA-bisamide complexes and their implication for stability and solution structure. Invest Radiol. 1991; 26(suppl 1):S226-S228.
14. Port M, Idee J-M, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
15. Idee J-M, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
16. Cacheris WP, Quay SC, Rocklage SM. The relationship between ther- modynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467-481.
17. Jackson GE, Wynchank S, Woudenberg M. Gadolinium (III) complex equilibria: the implications for Gd (III) MRI contrast agents. Magn Reson Med. 1990;16:57-66.
18. Tweedle MF, Hagan JJ, Kumar K. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991;9:409-415.
19. Laurent S, Vander Elst L, Copoix F, et al. Stability of MRI paramagnetic contrast media. A proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001;36:l 15-122.
20. Laurent S, Vander Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;l:128-137.
21. Sarka L, Burai L, Kiraly R, et al. Studies on the kinetic stabilities of the Gd(3+) complexes formed with the N-mono(methylamide), N′-mono(methylamide) and N,N″-bis(methylamide) derivatives of diethyl-enetriamine-N,N,N″,N″″,N″″-pentaacetic acid. J Inorg Biochem. 2002;91: 320-326.
22. Magerstadt M, Gansow OA, Brechbiel MW, et al. Gd(DOTA): an alternative to Gd-DTPA as Tl,2 relaxation agent for NMR imaging or spectroscopy. Magn Reson Med. 1986;3:808-812.
23. Albaaj F, Hutchinson AJ. Hyperphosphataemia in renal failure. Drugs. 2003;63:577-569.
24. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodia-mide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174-3178.
25. Barge A, Cravotto G, Gianolio E, et al. How to determine free Gd and free ligand in solutions of Gd chelates. A technical note. Contrast Media Mol Imaging. 2006; 1:184-188.
26. Ripley BD. Stochastic Simulation. New York, NY: Wiley; 1987.
27. R [computer program]. Version 2.6.1. Linear and Nonlinear Mixed Effects Models. R package version 3.1-86. Vienna, Austria: R Foundation for Statistical Computing; 2007.
28. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29:709-715.
29. Hamm B, Staks T, Muehler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
30. Sarka L, Burai L, Brücher E. The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2 + : a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. Chemistry. 2000;6:719-724.
31. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
32. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;7:130-137.
33. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
34. Schuhmann-Gampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991;26:975-979.
35. Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology. 2001;218:651-657.
36. Okada S, Katagiri K, Kumazaki T, et al. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339-341.
37. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol. 2002;178:105-109.
38. Brücher E. Kinetic stabilities of gadolinium (III) chelates used as MRI contrast agents. Top Curr Chem. 2002;221:103-122.
39. Toth E, Kiraly R, Platzek J, et al. Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(l-hydroxymethyl)-propyl]-l,4,7,10-tet- raazacyclododecane-l,4,7-triacetate. Inorg Chim Acta. 1996;249: 191-199.
40. Tóth E, Brücher E, Király R, et al. Kinetics of formation and dissociation of lanthanide (III)-DOTA complexes. Inorg Chem. 1994;33:4070-4076.
41. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76.
42. Sieber M, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
43. Sieber M, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis. Eur Radiol. 2008;18:2164-2173.
44. Sieber MA, Frenzel T, Lengsfeld P, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium based contrast agents. In: Proceedings of 16th Annual Meeting ISMRM. Toronto, Ontario; 2008:301:
45. Imura H, Choppin GR, Cacheris WP, et al. Thermodynamics and NMR studies of DTPA-bis(methoxyethylamide) and its derivatives. Protonation and complexation with Ln (III). Inorg Chim Acta. 1997;258:227-236.
46. Schmitt-Willich H, Brehm M, Ewers CLJ, et al. Synthesis and physico- chemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem. 1999;38:1134-1144.
47. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln (III) complexes (Ln-Gd, La, Lu). Inorg Chem. 1995;34:633-642.
48. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine [erratum in J Magn Reson Imag. 2007;26:217]. J Magn Reson Imag. 2006;24:1378-1385.
49. Caravan P, Comuzzi C, Crooks W, et al. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem. 2001;40:2170-2176.
50. Moreau J, Guillon E, Pierrard JC, et al. Complexing mechanism of the lanthanide cations Eu3 + , Gd3+, and Tb3+ with 1,4,7,10-tetrakis-(carboxymethyl) -l,4,7,10-tetraazacyclododecane (DOTA) - characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Chem Eur J. 2004; 10: 5218-5232.